Crovalimab - Chugai Pharmaceutical/Roche
Alternative Names: Anti-C5 recycling antibody - Chugai Pharmaceutical/Roche; CH-7092230; Crovalimab-akkz; Piasky; RG 6107; RO 7092230; RO-7112689; RO-711269; RO7112689/F01; SKY-59Latest Information Update: 03 Jul 2024
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Roche
- Class Antianaemics; Monoclonal antibodies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Paroxysmal nocturnal haemoglobinuria
- Phase III Atypical Haemolytic Uraemic Syndrome
- Phase II Sickle cell anaemia
- Phase I Lupus nephritis
Most Recent Events
- 28 Jun 2024 Committee for Medicinal Products for Human Use (CHMP) dopts a positive opinion for crovalimab for the treatment of Paroxysmal nocturnal haemoglobinuria in adults and adolescents (12 years of age or older with a weight of 40 kg) who are either new to, or have been previously treated with C5 inhibitors
- 20 Jun 2024 Registered for Paroxysmal nocturnal haemoglobinuria (In adolescents, In the elderly, In adults) in USA (IV)
- 20 Jun 2024 Registered for Paroxysmal nocturnal haemoglobinuria (In adolescents, In the elderly, In adults) in USA (SC)